APA (7th ed.) Citation

Horiuchi, H., Sasaki, H., Miyazaki, K., Miyata, N., Yoshimura, Y., & Tachikawa, N. (2022). Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(2), 329-332. https://doi.org/10.1016/j.jiac.2021.11.018

Chicago Style (17th ed.) Citation

Horiuchi, Hiroshi, Hiroaki Sasaki, Kazuhito Miyazaki, Nobuyuki Miyata, Yukihiro Yoshimura, and Natsuo Tachikawa. "Recovery from Severe Persistent COVID-19 Without Evidence of an Anti-SARS-CoV-2 Antibody Response in a Man with Mantle Cell Lymphoma Treated with Rituximab." Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy 28, no. 2 (2022): 329-332. https://doi.org/10.1016/j.jiac.2021.11.018.

MLA (9th ed.) Citation

Horiuchi, Hiroshi, et al. "Recovery from Severe Persistent COVID-19 Without Evidence of an Anti-SARS-CoV-2 Antibody Response in a Man with Mantle Cell Lymphoma Treated with Rituximab." Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, vol. 28, no. 2, 2022, pp. 329-332, https://doi.org/10.1016/j.jiac.2021.11.018.